LifeMD's business model primarily relies on employing full-time healthcare providers as a key differentiator from competitors.

LifeMD has grown to approximately 350,000 active patients across all 50 U.S. states, driven by its early adoption of GLP-1 medications.

There are ongoing discussions about potentially descheduling testosterone therapy in the United States.

LifeMD's transition from compounded GLP-1s to branded medications through partnerships with Eli Lilly and Novo Nordisk is a less profitable business model for the company.

GLP-1 related medications currently account for over 60% of LifeMD's top-line revenue.

The launch of direct-to-patient, self-pay programs for GLP-1 medications by Eli Lilly and Novo Nordisk has been a game-changer for the virtual care and pharmacy industry.

LifeMD has formed collaborations with both Eli Lilly and Novo Nordisk for prescribing branded GLP-1 medications.

Fewer than 15% of Americans who medically qualify for a GLP-1 medication are currently taking one.

Robert F. Kennedy Jr. has publicly discussed bringing new peptide therapies to the market.